Myotonic Dystrophy is an autosomal dominantly inherited multisystem disorder (MD type 1 and MD type 2). The main objective of forming a disease-oriented biobank is the structured storage of biomaterial and clinical data, both for research purposes within the Radboudumc and for (inter)national collaborations in the future. For both MD1 and MD2, investigation of DNA and pathophysiological mechanisms will be an important objective, with identification of targets for therapy.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Dutch-Nordic Alliance for Precision Cancer Medicine launched26 November 2021
The Nordic countries (Denmark, Sweden, Norway, and Finland) are together setting up national clinical precision cancer trials modelled on the very successful DRUP trial in the Netherlands.read more
New Automated PBMC isolation method introduced in LMI.21 September 2021
The Radboud Biobank (RB) and the laboratory of Medical Immunology (LMI) are making plans to replace the density gradient centrifugation method with a new automated PBMC isolation method, the AutoMACS Pro Separator.read more
Lysine Metabolism sub-biobank21 September 2021
Hereditary metabolic disorders form a large group of more than 1,400 rare disorders in which an error in the DNA causes abnormalities in the process in which proteins, fats and carbohydrates are converted into smaller building materials and energy.read more